About PolpharmaWe are the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. We actively operate in the markets of Central and Eastern Europe, the Caucasus and Central Asia.
ResponsibilityBeing the largest Polish pharmaceutical company we want to help people to live a healthy life in a healthy world. Social responsibility is an integral part of the management strategy in our company.
CareerPolpharma's development is possible only thanks to the commitment of our employees as well as the involvement of students and graduates in various business areas.
On 10 June, during a ceremony held at the Polish Prime Minister’s Office, Markus Sieger, CEO of Polpharma, signed an agreement with the Medical Research Agency to initiate the Warsaw Health Innovation Hub. This is the first initiative of its kind across Central Europe, aiming to bring together the public and business sectors in order to develop innovative medical, technological and legal solutions improving the health of patients and increasing the efficiency of the Polish healthcare system.The goal of the Warsaw Health Innovation Hub is to provide support in addressing and responding to public health challenges such as population ageing, epidemics of infectious and chronic diseases, and soaring costs relative to limited resources. The strategic partnership has developed four key priorities including:Fight against cancer – improved access to genomic diagnosticsFight against COVID-19 and its effectsStrengthening of e-health services – implementation of digital health solutions (e-services) to optimize patient treatmentDevelopment of Value-Based Healthcare – elaboration of regulations and digital solutions supporting the use of real world data (RWE)Within the framework of this initiative, Polpharma as an industry leader in Poland, wants to effectively support the needs of Polish patients, building added value for the healthcare system, particularly in terms of improving drug safety and pursuing goals in line with the Pharmaceutical Strategy for Europe, said Markus Sieger. Polpharma recognizes the need to ensure a sustainable supply chain and access to effective and affordable medicines as the key issues.In addition to Polpharma, the agreement was signed by Microsoft, Astra Zeneca, Roche, and EIT Health, which will assume the role of hub operator.
